Catching up with Bristol Myers and Merck, AstraZeneca declares neoadjuvant win for PD-L1/chemo combo
When AstraZeneca started the Phase III AEGEAN trial for Imfinzi in 2018, it was, alongside several Big Pharma brethren, hoping to push the use of PD-(L)1 therapies into earlier lines of treatment. Three and a half years later, the British drugmaker has nabbed promising data in a type of lung cancer.
Topline results from an interim analysis showed that adding Imfinzi to chemotherapy before surgery spurred a “statistically significant and meaningful” improvement in pathologic complete response for patients with resectable non-small cell lung cancer compared to chemotherapy alone.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.